|
Canada-QC-PINTENDRE selskapets Kataloger
|
Firma Nyheter:
- The pharmaceutical company AcuCort
AcuCort is an innovative pharmaceutical company that identifies, develops and commercializes smart drugs that meet the patient’s needs for a user-friendly and effective treatment
- AcuCort - Crunchbase Company Profile Funding
AcuCort’s vision is that Dexa ODF will be globally commercialized, be well integrated and used in the treatment risk management of acute allergic reactions and croup in children, and see wide use against chemotherapy-induced nausea and vomiting (CINV )
- AcuCort 2025 Company Profile: Stock Performance Earnings - PitchBook
AcuCort AB is an innovative biotechnology company that identifies, develops and commercializes smart drugs that meet the patient's needs for a user-friendly and effective treatment Contact Information
- AcuCort Company Profile - Office Locations, Competitors . . . - Craft
AcuCort is a company developing a drug candidate for the treatment of acute allergic reactions, croup, and chemotherapy-induced nausea and vomiting in children It offers ISICORT (previously named Dexa ODF), which is a fast-dissolving oral film containing the glucocorticoid dexamethasone, an anti-inflammatory substance
- AcuCort AB (NGM:ACUC) Company Profile Description - Stock Analysis
AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need
- AcuCort - Products, Competitors, Financials, Employees, Headquarters . . .
AcuCort is a pharmaceutical company focused on developing and commercializing drugs within the healthcare sector The company offers treatments based on existing substances, targeting areas with medical needs and focusing on simpler administration
- Acucort signs letter of intent for Zeqmelit in six European countries . . .
Life science company Acucort has entered into a letter of intent with global pharmaceutical company Glenmark Pharmaceuticals The letter of intent covers the distribution and marketing of Acucort's drug Zeqmelit in six European countries: Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine
- About AcuCort – Acucort
AcuCort is an innovative pharmaceutical company that identifies, develops and commercializes smart drugs that meet the patient’s needs for a user-friendly and effective treatment Potential drug candidates are based on existing and well-documented substances in indication areas…
- AcuCort signs its first commercial agreement for the companys drug . . .
LUND, Sweden, Nov 23, 2022 PRNewswire -- AcuCort AB (publ) (Spotlight Stock Market: ACUC) today announces that the company has signed an exclusive commercial agreement with the global
- History – Acucort
AcuCort is an innovative pharmaceutical company that identifies, develops and commercializes smart drugs that meet the patient’s needs for a user-friendly and effective treatment
|
|